The Scientific and Technological Research Council of Turkey   Report issue

Government Phase 1 Phase 2 Phase 3
Founded: Ankara Turkey (1963)

Organization Overview

First Clinical Trial
2014
NCT02061098
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Osman ERGANIS, PhD, Prof | The Scientific and Technological Research Council of Turkey

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autoimmune Diseases (Phase 1)

Colorectal Neoplasms (Phase 2)

Immune System Diseases (Phase 1)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Nasal Polyps (Phase 2)

Nasopharyngeal Neoplasms (Phase 2)

Nausea (Phase 3)

Neoplasms (Phase 3)

Overweight (Phase 2)

Postoperative Nausea and Vomiting (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Skin Diseases (Phase 1)

Urticaria (Phase 1)

Vomiting (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial APIs: 19